v3.24.0.1

Significant Transactions (Narrative) (Details) |  |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 19, 2022 USD ($) shares | Sep. 16, 2022 USD ($) | Nov. 01, 2021 USD ($) lease $ / shares shares | Aug. 23, 2021 USD ($) shares | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) item | Dec. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($)
General and administrative expenses |  |  |  |  | $ 2,961,000 | $ 7,794,000 | $ 6,508,000 | $ 12,882,000 |  |
Value of common stock issued |  |  |  |  | 30,000 |  | $ 30,000 |  |  | $ 20,000
Accrued expenses - noncurrent |  |  |  |  |  |  |  |  |  | 527,000
Purchase price allocated |  |  |  | $ 7,500,000 |  |  |  |  |  |
Secured Term Loan |  |  |  |  |  |  |  |  |  |
Secured term loan |  |  | $ 22,375,000 |  |  |  |  |  |  | 13,057,000
Interest rate (as percent) |  |  | 3.25% |  |  |  |  |  |  |
Cost incurred to attain debt |  |  |  |  |  |  |  |  |  | $ 120,000
RubrYc Therapeutics Inc [Member] |  |  |  |  |  |  |  |  |  |
Estimated fair value |  | $ 650,000 |  |  |  |  |  |  |  |
Milestone payments | $ 5,000,000 |  |  |  |  |  |  |  |  |
Amount advanced |  | 484,000 |  |  |  |  |  |  |  |
Transaction costs |  | 208,000 |  |  |  |  |  |  |  |
Finance leases |  | $ 814,000 | $ 814,000 |  |  |  |  |  |  |
Impairment of current prepaid expense |  |  |  |  |  |  |  |  | $ 288,000 |
Impairment of noncurrent prepaid expense |  |  |  |  |  |  |  |  | 864,000 |
Number of shares issued | shares | 5,117 |  |  |  |  |  |  |  |  |
Value of common stock issued | $ 1,000,000 |  |  |  |  |  |  |  |  |
Number of equipment leases | lease |  |  | 3 |  |  |  |  |  |  |
Purchase price allocated | $ 1,342,000 |  |  |  |  |  |  |  |  |
College Station Investors LLC And Bryan Capital [Member] |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  | $ 28,750,000 |  |  |  |  |  |  |
Cash payment |  |  | 28,000,000 |  |  |  |  |  |  |
Fair market value of property |  |  | $ 151,450 |  |  |  |  |  |  |
Percentage of base rent |  |  | 6.50% |  |  |  |  |  |  |
Cash consideration for equity interest acquired |  |  | $ 50,000 |  |  |  |  |  |  |
Number of warrants issued | shares |  |  | 2,579 |  |  |  |  |  |  |
Warrants, exercise price per share | $ / shares |  |  | $ 665 |  |  |  |  |  |  |
Shares issued under the Warrant | shares |  |  | 579 |  |  |  |  |  |  |
Fair value of the warrant |  |  | $ 217,255 |  |  |  |  |  |  |
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan |  |  |  |  |  |  |  |  |  |
Secured term loan |  |  | $ 22,375,000 |  |  |  |  |  |  |
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock |  |  |  |  |  |  |  |  |  |
Warrants issuable | shares |  |  | 1 |  |  |  |  |  |  |
Percentage of equity interest |  |  | 0.01% |  |  |  |  |  |  |
Separation Agreement and General Release [Member] |  |  |  |  |  |  |  |  |  |
General and administrative expenses |  |  |  |  |  | $ 2,130,000 |  |  |  |
Period of bi-monthly installments of current base salary |  |  |  |  |  |  | 24 months |  |  |
Period of bi-monthly installments of target bonus |  |  |  |  |  |  | 24 months |  |  |
Maximum period for coverage of health insurance |  |  |  |  |  |  | 18 months |  |  |
COBRA subsidy period |  |  |  |  |  |  | 18 months |  |  |
Number of times on which lump sum cash payment tis o be made | item |  |  |  |  |  |  | 6 |  |  |
Accrued expenses |  |  |  |  | $ 1,100,000 |  | $ 1,100,000 |  |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member] |  |  |  |  |  |  |  |  |  |
Collaboration and license agreement, agreement term |  |  |  | 5 years |  |  |  |  |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics Inc [Member] |  |  |  |  |  |  |  |  |  |
Collaboration and license agreement, royalty payment term |  |  |  | 10 years |  |  |  |  |  |
Series A-2 Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |
Purchase price allocated |  |  |  |  |  |  |  |  | $ 1,760,000 |
Series A-2 Preferred Stock [Member] | Series A-2 Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |
Purchase price allocated |  |  |  | $ 1,760,000 |  |  |  |  |  |
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member] |  |  |  |  |  |  |  |  |  |
Stock purchase agreement, number of shares purchased | shares |  |  |  | 2,864,345 |  |  |  |  |  |
Stock purchase agreement, value of shares purchased |  |  |  | $ 7,500,000 |  |  |  |  |  |

X
- Definition Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period. + References No definition available. + Details
Name: | ibio_AccruedLiabilitiesNoncurrent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect an asset acquisition. + References No definition available. + Details
Name: | ibio_AssetAcquisitionTransactionCosts
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of base rent payable on percentage of fair Market Value of the Property. + References No definition available. + Details
Name: | ibio_BaseRentPercentageOfFairMarketValueOfProperty
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, agreement term + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementAgreementTerm
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, royalty payment term + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments based on different scenarios. + References No definition available. + Details
Name: | ibio_CollaborativeArrangementMilestonePayments
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration transferred for equity interest acquired under the equity agreement. + References No definition available. + Details
Name: | ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity agreement, percentage of equity interest issued or issuable. + References No definition available. + Details
Name: | ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrants issued or issuable under the equity agreement. + References No definition available. + Details
Name: | ibio_EquityAgreementWarrantsIssuedOrIssuable
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair market value of the property. + References No definition available. + Details
Name: | ibio_FairMarketValueOfProperty
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Impairment of current prepaid expenses. + References No definition available. + Details
Name: | ibio_ImpairmentOfPrepaidExpensesCurrent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment of non-current prepaid expenses. + References No definition available. + Details
Name: | ibio_ImpairmentOfPrepaidExpensesNonCurrent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the number of equipment leases. + References No definition available. + Details
Name: | ibio_NumberOfEquipmentLeases
Namespace Prefix: | ibio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests. + References No definition available. + Details
Name: | ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests. + References No definition available. + Details
Name: | ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period. + References No definition available. + Details
Name: | ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"). + References No definition available. + Details
Name: | ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"). + References No definition available. + Details
Name: | ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct
Namespace Prefix: | ibio_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of bi-monthly installments of current base salary to be paid under severance benefits. + References No definition available. + Details
Name: | ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of bi-monthly installments of target bonus to be paid under severance benefits. + References No definition available. + Details
Name: | ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock purchase agreement, number of shares purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementNumberOfSharesPurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock purchase agreement, value of shares purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementValueOfSharesPurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of warrants issued for the final payment of rent due under sublease. + References No definition available. + Details
Name: | ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of warrants issued for the final payment of rent due under sublease. + References No definition available. + Details
Name: | ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D + Details
Name: | us-gaap_DeferredFinanceCostsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Present value of lessee's discounted obligation for lease payments from finance lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details
Name: | us-gaap_FinanceLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsForAdvanceToAffiliate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |